【作者】 王晋芬； 王毅； 郭素堂；

【Author】 Wang Jin-Fen Wang Yi Guo Su-Tang Deptment of Pathology, Shanxi Tumor Hospital, Taiyuan 030013 China

【机构】 山西省肿瘤医院病理科；

【摘要】 目的:用表面增强激光解吸电离飞行时间质谱 (surface enhanced laser desorption／ionization time of flight mass spectrometry,SELDI-TOF-MS)技术检测非霍奇金淋巴瘤患者的血清蛋白质谱的差异性表达,以期寻找淋巴瘤的诊断标志物。方法:运用免疫组织化学检测40 例非霍奇金淋巴瘤患者的淋巴瘤组织中bcl-2,bcl-6,CD3, CD5,CD15,CD20,CD23,CD30,CD56,CD79 α,PAX5和 TdT的表达,参照《2001年WHO淋巴组织肿瘤分类》,确定病理学诊断。用SELDI-TOF-MS技术分析上述患者血清的WCX2蛋白芯片表达图谱,并用Biomarker Wizard软件对数据进行分析。结果:根据免疫组织化学结果将40例样本确切诊断分类,其中B细胞淋巴瘤27例,T细胞淋巴瘤13例。血清样本在质荷比位于2-20k的范围内,总共检测到157个有效的蛋白质波峰。经软件分析发现共有5个波峰强度值在B细胞淋巴瘤与T细胞淋巴瘤间存在明显差异 (P<0．05)。其中B细胞淋巴瘤组中m／z位于8083、15944、 7979、16110、8057的5个波峰强度值均高于T细胞淋巴瘤组。结论:结合免疫组织化学和SELDI蛋白芯片技术可检测淋巴瘤患者特异性标志物,有一定的临床应用前景。更多还原

【Abstract】 Objective: Screen serum protein expression maps in patients with non-Hodgkin lymphoma(NHL) by using surface enhanced laser desorption/ionization time of flight mass spectrometry(SELDI-TOF-MS), and to find the biomarkers in NHL for early stage diagnosis. Methods: Using immunohistochemical method to investigate the ex- pression of bcl-2, bcl-6, CD3, CD5, CD15, CD20, CD23, CD30, CD56, CD79 a, PAX5 and TdT in the lymphoma tissues of 40 NHL, which were classified according to WHO classification Tumours of Haematopoietic and Lymphoid Tissues, and using SELDI-TOF-MS to analyze sera of these cases on WCX2 protein chip. The data was analyzed by Biomarker Wizard software. Results: 40 cases was diagnosised and classified specifically according the im-munohistochemical method, including 27 B-cell lymphoma and 13 T - cell lymphoma. 157 protein peaks were detected in the molecular range of 2-20k, among which 5 ones were significantly different between T and B-cell Iymphoma (p<0.05). Peaks of 8083, 15944, 7979, 16110 and 8057 Da were upregulated in B-cell lymphoma cases. Conclusion: The specific early stage biomarkers of NHL could be detected using immunohistochemical method and SELDI-TOF-MS, which had a bright prospect of clinical application.更多还原